Metformin sustained release pharmacokinetics
Pro Research Analysisby 
Searched over 200M research papers
Metformin Sustained Release Pharmacokinetics: Key Parameters and Comparisons
Pharmacokinetic Profiles of Sustained Release (SR) Metformin
Sustained release (SR) formulations of metformin are designed to release the drug more slowly, resulting in a delayed time to reach maximum plasma concentration (Tmax), lower peak concentration (Cmax), and often a longer mean residence time (MRT) and half-life compared to immediate release (IR) formulations. Studies consistently show that SR metformin achieves a Tmax of about 3.8–4.6 hours, compared to 1–3 hours for IR formulations, and a Cmax that is slightly lower or comparable to IR, depending on the specific formulation and dosing regimen 1237.
Bioavailability and Systemic Exposure
The overall systemic exposure, measured by area under the curve (AUC), for SR metformin is generally similar to that of IR metformin, indicating comparable bioavailability. For example, one study found the relative bioavailability of SR tablets to be about 98.4% compared to reference tablets, with no significant differences in key pharmacokinetic parameters such as AUC and Cmax 14. However, some studies report a slight decrease in AUC for SR formulations, which may be due to the slower and more prolonged absorption 23.
Steady-State and Multiple Dose Pharmacokinetics
After multiple doses, SR metformin maintains more stable plasma concentrations, with higher trough (Cmin) levels and less fluctuation between peak and trough compared to IR formulations. This results in a smoother pharmacokinetic profile, which may help reduce gastrointestinal side effects and improve tolerability 134.
Fixed-Dose Combinations and Dose Proportionality
SR metformin is often combined with other antidiabetic agents, such as glimepiride or gemigliptin, in fixed-dose combinations. Studies show that these combinations maintain the pharmacokinetic properties of each component, with SR metformin showing delayed Tmax and similar or slightly reduced AUC compared to IR combinations. Dose proportionality is observed, and the safety profiles are comparable between different SR dose strengths 279.
Novel Sustained Release Approaches
Innovative SR formulations, such as metformin-loaded poly(lactic acid) (PLA) microparticles and sulfenamide prodrugs, have been explored to further prolong metformin release. These approaches result in even longer Tmax, increased MRT and half-life, and lower Cmax, but may also reduce bioavailability. Such systems show promise for long-term disease management, though further optimization is needed to address the decrease in bioavailability 5610.
Conclusion
Metformin sustained release formulations provide a delayed and prolonged absorption profile, resulting in lower peak concentrations, longer time to peak, and more stable plasma levels compared to immediate release forms. These pharmacokinetic characteristics are consistent across various studies and formulations, supporting the use of SR metformin for improved tolerability and patient compliance, especially in combination therapies. Novel SR delivery systems may offer further benefits, but require careful evaluation to ensure adequate bioavailability.
Sources and full results
Most relevant research papers on this topic
Study of pharmacokinetics and relative bioavailability of metformin hydrochloride sustained-release tablets
The two preparations of metformin hydrochloride sustained-release tablets show bioequivalent pharmacokinetics and relative bioavailability.
The pharmacokinetics of metformin: a comparison of the properties of a rapid-release and a sustained-release preparation.
Rapid-release metformin has a shorter peak serum level and longer elimination half-life, but both preparations have similar pharmacokinetic properties and gastrointestinal side effects.
An in vivo pharmacokinetic study of metformin microparticles as an oral sustained release formulation in rabbits
Metformin-loaded PLA microparticles show potential for oral sustained release in rabbits, with shorter Tmax, longer MRT and half-life, decreased Cmax, and prolonged release expected for metformin.
Potential of Sustained Release Microparticles of Metformin in Veterinary Medicine: An in Vivo Pharmacokinetic Study of Metformin Microparticles as Oral Sustained Release Formulation in Rabbits.
Sustained-release microparticles of metformin, loaded within poly lactic acid (PLA) polymer, show promise for prolonged/sustained release after oral administration in various animal species affected by insulin disorders.
DOI